SKNJCT-001
Basal Cell Carcinoma (BCC)
Phase IIActive
Key Facts
About Medicus Pharma
Medicus Pharma is a micro-cap biotech focused on developing intralesional therapies for dermatological oncology, primarily basal cell carcinoma (BCC). Its strategy is anchored on the proprietary SkinJect™ delivery platform, which aims to maximize local drug efficacy while minimizing systemic side effects. The company's primary achievement is advancing its lead candidate, SKNJCT-001, into Phase II clinical trials. As a publicly traded entity on the TSX Venture Exchange, Medicus represents a high-risk, high-reward investment opportunity in the niche but growing field of non-invasive skin cancer treatments.
View full company profileTherapeutic Areas
Other Basal Cell Carcinoma (BCC) Drugs
| Drug | Company | Phase |
|---|---|---|
| BO-112 | Highlight Therapeutics | Phase 2b |
| Skinject Patch | Skinject | Pre-clinical |